Acta Cardiologica, Journal Year: 2024, Volume and Issue: unknown, P. 1 - 3
Published: Dec. 16, 2024
Language: Английский
Metabolism and Target Organ Damage, Journal Year: 2025, Volume and Issue: 5(1)
Published: March 27, 2025
Fatty liver disease associated with metabolic dysfunction has emerged as a significant global health challenge. This condition often coexists other diseases, such alcohol-related and viral hepatitis, complicating both diagnosis management. To address the limitations of non-alcoholic fatty (NAFLD) classification, two alternative frameworks have been proposed: dysfunction-associated (MAFLD) in 2020 steatotic (MASLD) 2023. A key difference between these definitions is how they consider relation to coexistence conditions. MAFLD adopts dual etiology concept, creating unified classification system that aligns contemporary clinical epidemiological needs. In contrast, MASLD introduces new term, MetALD (metabolic alcohol-related/associated disease), describe patients who excessive alcohol intake. review critically examines clinical, research, implications differing approaches MASLD, offering insights into their potential enhance understanding management multi-etiology diseases.
Language: Английский
Citations
1
Antioxidants, Journal Year: 2024, Volume and Issue: 13(11), P. 1386 - 1386
Published: Nov. 14, 2024
Background: The gut microbiota constitutes a complex microorganism community that harbors bacteria, viruses, fungi, protozoa, and archaea. human bacterial has been extensively proven to participate in metabolism, immunity, nutrient absorption. Its imbalance, namely “dysbiosis”, linked disordered metabolism. Metabolic dysfunction-associated steatotic liver disease (MASLD) is one of the features deranged metabolism leading cause cirrhosis hepatocellular carcinoma. Thus, there pathophysiological link between dysbiosis MASLD. Aims Methods: We aimed review literature data on composition its MASLD describe concept “gut–liver axis”. Moreover, we reviewed approaches for modulation treatment. Results: There consolidated evidence particular associated with stages. model explaining relationship bidirectional organization, physiopathology Oxidative stress keystones pathophysiology fibrosis generation. promising efficacy pre- probiotics reversing patients, therapeutic effects. Few yet encouraging fecal transplantation (FMT) are available literature. Conclusions: characteristic key target reversal treatment via diet, pre/probiotics, FMT remains treatment, prevention, reversal.
Language: Английский
Citations
4
Metabolism and Target Organ Damage, Journal Year: 2025, Volume and Issue: 5(1)
Published: March 8, 2025
The transition from non-alcoholic fatty liver disease (NAFLD) to metabolic dysfunction-associated steatotic (MASLD) represents a significant evolution in the nomenclature of disease. This updated terminology emphasizes dysfunction as central criterion, offering greater precision and improved risk stratification. MASLD broadens scope classification by incorporating individuals with diverse profiles, including lean patients hepatic steatosis, aligns clinical practice multifactorial nature this condition. global adoption creates opportunities for standardization research settings, facilitating multicenter collaborations enhancing development diagnostic tools therapeutic strategies. However, new poses challenges, potential confusion during implementation, cultural linguistic barriers, integration MetALD, need educational initiatives targeting healthcare providers patients. Further efforts are required refine criteria, address implementation seamlessly incorporate into international coding systems. review evaluates key advantages ongoing challenges associated MASLD, providing comprehensive analysis its impact on practice, research, health
Language: Английский
Citations
0
Expert Review of Endocrinology & Metabolism, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 12
Published: April 12, 2025
In 2023, metabolic dysfunction-associated steatotic liver disease (MASLD) was introduced following fatty (MAFLD). Both aim to address the limitations of nonalcoholic (NAFLD). This review analyzes similarities and differences between MAFLD MASLD, focusing on their impacts epidemiology, diagnosis, stigma, related diseases. Current evidence suggests that criteria effectively identify individuals at higher risk through a good balance sensitivity specificity. Moreover, is more generalizable term easily understood globally. The transition from NAFLD MASLD marks significant advance in understanding within hepatology. identifies homogeneous cohort patients with due dysfunction provides valuable framework for holistic, patient-centered management strategies consider various contributing factors improve health outcomes.
Language: Английский
Citations
0
Journal of Nutrition College, Journal Year: 2025, Volume and Issue: 14(2), P. 136 - 155
Published: Jan. 2, 2025
ABSTRACTMetabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty (NAFLD), affects more than one-third of the adult population and over ten percent children. The global prevalence MASLD is estimated to range from 32% 37.3%, with higher in men individuals obesity. pathophysiology highly complex, starting excessive lipid accumulation liver, oxidative stress, mitochondrial dysfunction, ending disruptions gut-microbiota-liver axis. In last decade, gastrointestinal microbiota has been recognized a major regulator energy homeostasis metabolism, imbalance affecting adipose tissue, muscle. Components metabolites, such short-chain acids (SCFA) branched-chain amino (BCAA), play crucial role gut-host-microbiome metabolic axis development MASLD. This review discusses relationship between microbiota-related metabolites detected through metabolomics, well potential SCFAs BCAAs biomarkers for early detection MASLD.Keyword : Microbiota; metabolite; (MASLD); (SCFA); (BCAA) ABSTRAKMetabolic sebelumnya dikenal sebagai mempengaruhi lebih dari sepertiga populasi dewasa dan sepuluh persen anak-anak. Prevalensi diperkirakan mencapai hingga 37,3% secara global, dengan prevalensi yang tinggi pada laki-laki individu obesitas. Patofisiologi sangat kompleks, dimulai akumulasi berlebihan di hati, stres oksidatif, disfungsi mitokondria, berakhir gangguan microbiota-gut-liver-axis. Dalam 10 tahun terakhir, mikrobiota saluran cerna telah dikenali pengatur utama energi metabolisme, ketidakseimbangan metabolisme jaringan adiposa, otot. Komponen metabolit mikrobiota, seperti asam lemak rantai pendek atau acid cabang berperan penting dalam jalur gut host-microbiome perkembangan Ulasan ini membahas hubungan antara terkait terdeteksi melalui metabolomik, serta peran SCFA BCAA biomarker potensial deteksi dini MASLD.Kata kunci Mikrobiota; metabolit;
Language: Английский
Citations
0
Metabolism and Target Organ Damage, Journal Year: 2024, Volume and Issue: 4(4)
Published: Dec. 9, 2024
The recent shift from “non-alcoholic fatty liver disease” (NAFLD) and “metabolic associated (MAFLD) to dysfunction-associated steatotic (MASLD) has raised questions about its scientific basis impact on patient understanding. This renaming may create confusion rather than clarity. A collaborative approach involving healthcare professionals, researchers, patients establish terminology that balances accuracy with accessibility is needed. Effective disease naming should be accurate, unique, consistent, objective, accessible - qualities essential for clear communication in healthcare. Disease name more correctness because conventions public use, especially anything related health, must a matter of convenience, ethics, cultural social acceptance. Education straightforward take precedence over renaming, helping providers fully understand the complexities implications treatment. After all, health perspective, MAFLD advantages MASLD.
Language: Английский
Citations
1
Acta Cardiologica, Journal Year: 2024, Volume and Issue: unknown, P. 1 - 3
Published: Dec. 16, 2024
Language: Английский
Citations
1